BU Law Professors Plan to Study Impact of Biopharmaceutical Funder CARB-X
Professors Michael Meurer and James Bessen join interdisciplinary team examining data from BU Law-based accelerator.
CARB-X Funds SciBac to Develop a Microbe Drug that Kills C. Difficile Superbugs
An alternative to antibiotics, this microbe pill would boost the body’s microbiome to kill the Clostridium difficile bacteria and prevent recurrent C. difficile infections.
CARB-X Funds Summit Therapeutics to Support Development of a New Class of Antibiotic to Treat Gonorrhoea Superbug
New class of antibiotics targets the urgent global threat of gonorrhoea bacterial infections.
BU-based Antimicrobial Partnership Gets Another $50 Million Plus
Gates Foundation and UK government contributions push CARB-X funding to more than $500 million.
Huberfeld, Outterson Update The Law of American Health Care
For the casebook’s second edition, the authors address changes to the ACA shaped by the Trump administration.
CARB-X Awards Seres Therapeutics $2.5M to Develop a Microbiome to Prevent Bacterial Infections
The company may receive $3.1M more if certain milestones are met to to prevent serious bacterial infections and graft versus host disease in transplant patients.
CARB-X Announces an Award of up to $5.4M to Vedanta Biosciences
CARB-X portfolio now has 23 early development projects with multiple innovative approaches to tackle the most difficult resistant infections.
CARB-X Backs Integrated Biotherapeutics to Prevent Drug-Resistant MRSA Infections
CARB-X portfolio gains first vaccine project—a highly innovative approach to the prevention of life-threatening infections often contracted in hospitals.
CARB-X Awards INHIBRx up to $4.55M to Accelerate the Development of a Novel Antibody
CARB-X portfolio now has 21 early development projects aimed at treating life-threatening bacterial infections and battling the growing global threat of drug-resistance.
CARB-X Awards Amicrobe $2.48M
Funding will accelerate the development of the first topically applied antimicrobial in the CARB-X portfolio for use on infected tissue in surgical, emergency, and post-disaster settings.